ERRATUM: Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction. [PDF]
Apaijai N +4 more
europepmc +1 more source
ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj +8 more
wiley +1 more source
Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. [PDF]
Aloke C +4 more
europepmc +1 more source
ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires +10 more
wiley +1 more source
Glucagon-Like Peptide-1 Receptor Agonists vs Dipeptidyl Peptidase-4 Inhibitor Use on Risk of Asthma Exacerbation Among Diabetic Patients with Co-Morbid Asthma in Hong Kong. [PDF]
Kwok WC +5 more
europepmc +1 more source
SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu +6 more
wiley +1 more source
Identification of distinct epitopes in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. [PDF]
Mai S +6 more
europepmc +1 more source
Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective
Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac +7 more
wiley +1 more source
Machine Learning Exploration of Food-Derived Chemical Space for Potential Nutritional Metabolic Regulators Targeting Dipeptidyl Peptidase-4. [PDF]
Alzunaidy NA.
europepmc +1 more source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source

